World Courier Receives Wholesale Distribution Authorisation
World Courier, an AmerisourceBergen company, has been granted Wholesale Distribution Authorisation (WDA) by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The WDA is a benchmark certifying the company’s quality systems and processes for storing and distributing pharmaceuticals.
World Courier received the WDA certification following an application process and inspection by MHRA. Designed to ensure patients safely receive their proper medications, the regulation serves as a verification measure to enforce the European Union’s Falsified Medicine Directive. MHRA regulations require WDA for companies that store shipments of pharmaceutical products for longer than 36 hours or have a refrigerated storage facility for pharmaceuticals. The company also met requirements to demonstrate compliance with the European Union’s Good Distribution Practice (GDP), guidelines that regulate the storage and transportation of medicinal products intended for human consumption.
“Becoming one of the first specialty logistics companies to acquire Wholesale Distribution Authorisation in the UK is a significant accomplishment for AmerisourceBergen, World Courier and our clients,” said Simon Beaumont, Managing Director for World Courier in the UK. “As the global leader in specialty logistics, we continuously strive to offer our clients the best possible integrated supply chain services to improve the quality and accountability in the transportation, dispensing and storage of pharmaceutical products. The WDA accreditation recognises these efforts and demonstrates our commitment to a safe, secure and efficient specialty pharmaceutical supply chain.”
With World Courier receiving WDA accreditation, shipments of pharmaceuticals to the company’s UK location can be stored in MHRA-approved temperature controlled areas over extended periods of time, such as a weekend. Clients can rely on World Courier to be compliant with the MHRA requirements including equipment, documentation and qualified sub-contractors. Additionally, the supply chain’s security is improved by enhanced security and traceability of the shipments, as per MHRA standards.
The WDA accreditation is one way AmerisourceBergen continues to connect patients to vital treatments when and where they need them. Safe and timely delivery of medication is critical to the success of clinical trials and to patients accessing licensed medicinal products.
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...